ReviewCureus2023
Oral Submucous Fibrosis: A Review of the Current Concepts in Management.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Tropomyosin-1 positively regulates TGF-β/Smad3 signaling through STUB1 in arecoline-induced oral submucosal fibrosis.Odontology · 2026Article
- Hypoxia and angiogenesis across clinical stages of oral submucous fibrosis: implications for oral carcinogenesis.BMC oral health · 2026Article
- Jiawei Danxuan Koukang and Its Component Kaempferol Alleviate Oral Submucous Fibrosis by Restoring Epithelial-Fibroblast Homeostasis and Suppressing Neutrophil Recruitment via the ANXA1/FPR2 Axis.Food science & nutrition · 2026Article
- A systematic review of staging systems for oral submucous fibrosis: evolution, variations, and clinical implications.Frontiers in oral health · 2026Review
- The multifaceted role of oral microbiota-host interactions in oral submucous fibrosis: from pathogenic mechanisms to microecological regulation therapies.Frontiers in microbiology · 2026Review
- Isoliquiritigenin represses the pro-fibrotic TGF-β/smad2 signaling and nuclear enriched abundant transcript 1 (NEAT1) in oral submucous fibrosis.Journal of dental sciences · 2026Article
- Distinctive tumor biology of oral squamous cell carcinoma associated with oral submucous fibrosis and its suppressive immune microenvironment.BMC oral health · 2025Article
- In vivo quantification of viscoelastic property alterations in oral submucous fibrosis using optical coherence elastography.Biomedical optics express · 2025Article
- New frontiers in oral submucous fibrosis: The promise of collagen based interventions.Bioinformation · 2025Article
- Echoes of healing: evaluating therapeutic ultrasound in oral submucous fibrosis - An experimental study.Bioinformation · 2025Article
- Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma.Cancers · 2024Review
- SFRP1 reduces neutrophil infiltration and inhibits the Wnt/β-catenin pathway to alleviate oral submucous fibrosis.In vitro cellular & developmental biology. Animal · 2024Article
- Oral Health and Nutraceutical Agents.International journal of molecular sciences · 2024Review
- New Perspectives about Relevant Natural Compounds for Current Dentistry Research.Life (Basel, Switzerland) · 2024Review
- Transoral Robotic Surgery for Oral Cancer: Evaluating Surgical Outcomes in the Presence of Trismus.Cancers · 2024Article
- Article
- Immunoglobulin G (IgG) in oral submucous fibrosis and oral squamous cell carcinoma - AnJournal of oral and maxillofacial pathology : JOMFPArticle
- Comparative evaluation of intralesional platelet-rich plasma and triamcinolone in management of oral submucous fibrosis: A prospective clinical study.Journal of oral biology and craniofacial researchArticle
- Dental pulp stem cells as a novel antifibrotic therapy for oral submucous fibrosis: An in vitro study.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSMF) is a precancerous disorder of the submucosa that causes inflammation and progressive fibrosis, leading to pronounced stiffness and trismus. Chewing betel nuts is a significant risk factor for OSMF in India. Arecoline from betel nuts and copper, which causes fibroblast dysfunction and the development of fibrotic bands, are the main components of betel quid. OSMF is distinguished by fibrosis in the submucosal region, which affects the majority of the oral cavity and results in advanced lockjaw due to rigidity in the lips, pharynx, cheeks, and upper third of the oesophageal canal, which progresses to dysphagia. The prevalence of OSMF is rising, particularly among younger generations, as more commercially available areca nut products like gutka (chewing tobacco) and others are being introduced. The severity of OSMF develops as the practice continues and is permanent. It also persists even after chewing has been stopped. The hallmark of oral submucous fibrosis (OSF) is abnormal collagen deposition. It is a precancerous condition and progresses to malignant tumours. Symptoms include ulcers, xerostomia, submucous fibrosis, burning sensation, and a reduction in mouth opening. Each of these drastically reduces the patient's quality of life. In the past, many treatment modalities have been tried but none of them has resulted in a cure for the disease. The primary focus of the treatment is to reduce the signs and symptoms so that the patient can have a better quality of life. Along with principles, conservative, medical, and surgical management issues have also been covered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.